GlassScriptPhysician profile
Christopher M Bergeron
NPI 1508851775
$62,971.01
in general payments reported to CMS, 2019-2025
19 companies · $21K in 2025
The $21K reported for 2025 was more than what 98% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,501 · 2020: $3,816 · 2021: $664 · 2022: $752 · 2023: $13K · 2024: $22K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $45K · Travel and Lodging: $7,713 · Food and Beverage: $2,254 · Long Term Medical Supply Or Device Loan: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $45,048.25 |
| Travel and Lodging | $7,712.74 |
| Food and Beverage | $2,254.30 |
| Long Term Medical Supply Or Device Loan | $222.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $50,097.03 | 2019-2025 | Scopis Ent, Xpress Ent Dilation System, Tgs Guidewire |
| Regeneron Pharmaceuticals, INC. | $5,035.64 | 2023-2024 | Dupixent |
| Optinose US, INC. | $3,884.63 | 2019-2022 | |
| Genzyme Corporation | $2,216.21 | 2019-2022 | |
| Integra Lifesciences Corporation | $653.51 | 2022-2025 | Trudi Probe, Inspira Air, Acclarent Aera |
| Acclarent, INC | $210.48 | 2021-2022 | |
| Amgen INC. | $193.70 | 2025 | Tepezza |
| Medtronic, INC. | $183.24 | 2021-2025 | Propel |
| Karl Storz Endoscopy-America | $151.37 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $67.13 | 2025 | |
| Medtronic USA, INC. | $55.54 | 2020 | |
| Neurent Medical Limited | $54.28 | 2023 | Neuromark Device, Neuromark Radiofrequency Console |
| Brainlab, INC. | $40.66 | 2024 | Surgical Planning and Navigation Radiation Treatment Planning and Positioning |
| Glaxosmithkline, LLC. | $33.13 | 2023 | Nucala |
| Amag Pharmaceuticals, INC. | $23.97 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acera Surgical, INC. | $20.13 | 2024 | Restrata Wound Matrix |
| Phadia US INC. | $17.62 | 2023 | Immunocap |
| Baxter Healthcare | $17.46 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bergeron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.